This dataset provides performance ratings for California Surgeons for Risk-Adjusted Operative Mortality Rates for Coronary Artery Bypass Graft (CABG) Surgery from 2011 to 2018. It also includes the number of isolated CABG surgery cases and deaths that each surgeon performed as well as the location of hospitals where the surgeon performed CABG surgery.

CABG surgery, a major interventional procedure to treat coronary artery diseases, is the most common type of open-heart surgery and the costliest procedure in California. It is known that there are large disparities in the use of CABG procedures and outcomes by assigned sex at birth and by race/ethnicity. Understanding changes in CABG utilization and outcome by assigned sex at birth and race/ethnicity over time is important in the evaluation of hospital resources, regional health policy, quality improvement, and the promotion of health equity.

CABG surgery, a major interventional procedure to treat coronary artery diseases, is the most common type of open-heart surgery and the costliest procedure in California. It is known that there are large disparities in the use of CABG procedures and outcomes by assigned sex at birth and by race/ethnicity. Understanding changes in CABG utilization and outcome by assigned sex at birth and race/ethnicity over time is important in the evaluation of hospital resources, regional health policy, quality improvement, and the promotion of health equity.

The treatment of patients with coronary artery disease continues to evolve; all three strategies – medical therapy, surgical revascularization, and percutaneous coronary intervention – have changed. Medical therapy with intense risk-factor modification and treatment with a statin, aspirin, and angiotensin-converting enzyme (ACE) inhibitors, should be used unless contraindicated. Surgical therapy has also changed with the introduction of minimally invasive, beating heart surgery. Percutaneous coronary intervention has perhaps changed the most radically with adjunctive therapy – glycoprotein IIb/IIIa inhibitors, thienopyridines, and reliance on stent implantation. The future, with new distal protection devices and drug-coated stents, should continue to see increased numbers of patients who can benefit from percutaneous intervention.

This report uses data from the California Cardiovascular Outcomes Reporting Program (CCORP) for Coronary Artery Bypass Graft (CABG) to provide comparisons of readmissions due to isolated CABG complications from 2018 to 2022. These years are the most recently available data that is used by CCORP in its mandated annual performance reporting.

This report uses data from the California Cardiovascular Outcomes Reporting Program (CCORP) for Coronary Artery Bypass Graft (CABG) to provide comparisons of readmissions due to isolated CABG complications from 2018 to 2021. These years are the most recently available data that is used by CCORP in its mandated annual performance reporting.

(See Note below regarding 2015 data). The dataset contains hospitalization counts and rates (age 18+), statewide and by county, for 7 potentially-preventable adverse events that occur during a hospital stay. They provide a perspective on complications and iatrogenic events and help assess total incidence within a region. The measures, based upon the Agency for Healthcare Research and Quality’s (AHRQ’s) Patient Safety Indicators (PSIs), include: retained surgical item or unretrieved device fragment, iatrogenic pneumothorax, central venous catheter-related blood stream infection, postoperative wound dehiscence, accidental puncture or laceration, transfusion reaction, and perioperative hemorrhage or hematoma. Note: HCAI is only releasing the first 3 quarters of 2015 data due to a change in the reporting of diagnoses/procedures from ICD-9-CM to ICD-10-CM/PCS effective October 1, 2015, and the inability of the AHRQ software to handle both code sets concurrently.